Shares of Infinity Pharmaceuticals Inc. (NASDAQ:INFI) have been assigned an average rating of “Hold” from the seven brokerages that are covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, two have given a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $2.83.

Several brokerages have recently issued reports on INFI. Zacks Investment Research upgraded shares of Infinity Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.00 target price for the company in a report on Tuesday, September 25th. JPMorgan Chase & Co. cut shares of Infinity Pharmaceuticals from a “neutral” rating to an “underweight” rating in a report on Monday, November 12th. Wells Fargo & Co downgraded shares of Infinity Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Monday, November 12th. UBS Group restated a “reduce” rating on shares of Infinity Pharmaceuticals in a research note on Monday. Finally, B. Riley started coverage on shares of Infinity Pharmaceuticals in a research note on Friday, January 4th. They issued a “buy” rating and a $3.00 price objective for the company.

In other Infinity Pharmaceuticals news, major shareholder Bvf Partners L. P/Il purchased 604,208 shares of the firm’s stock in a transaction that occurred on Tuesday, November 13th. The stock was purchased at an average price of $1.35 per share, for a total transaction of $815,680.80. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Value Fund L. P. Biotechnology purchased 1,469,826 shares of the firm’s stock in a transaction that occurred on Wednesday, November 21st. The shares were acquired at an average price of $1.37 per share, with a total value of $2,013,661.62. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 3,905,634 shares of company stock valued at $5,300,055. Insiders own 11.45% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the company. Northpointe Capital LLC acquired a new stake in Infinity Pharmaceuticals during the 3rd quarter worth approximately $1,433,000. Fosun International Ltd acquired a new stake in Infinity Pharmaceuticals during the 3rd quarter worth approximately $879,000. Opaleye Management Inc. acquired a new stake in shares of Infinity Pharmaceuticals during the third quarter worth $745,000. Essex Investment Management Co. LLC lifted its holdings in shares of Infinity Pharmaceuticals by 121.4% during the third quarter. Essex Investment Management Co. LLC now owns 364,401 shares of the biotechnology company’s stock worth $988,000 after purchasing an additional 199,796 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Infinity Pharmaceuticals by 27.0% during the second quarter. Dimensional Fund Advisors LP now owns 932,370 shares of the biotechnology company’s stock worth $1,781,000 after purchasing an additional 198,098 shares during the period. Institutional investors and hedge funds own 52.16% of the company’s stock.

INFI traded up $0.02 on Friday, reaching $1.31. The company’s stock had a trading volume of 213,300 shares, compared to its average volume of 220,250. The company has a market capitalization of $73.36 million, a price-to-earnings ratio of -1.58 and a beta of 2.29. Infinity Pharmaceuticals has a fifty-two week low of $1.00 and a fifty-two week high of $2.92.

Infinity Pharmaceuticals (NASDAQ:INFI) last announced its quarterly earnings results on Monday, November 5th. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.14) by $0.37. The business had revenue of $22.00 million during the quarter. On average, equities research analysts predict that Infinity Pharmaceuticals will post -0.23 EPS for the current fiscal year.

About Infinity Pharmaceuticals

Infinity Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study.

Featured Story: How does a reverse stock split work?

Analyst Recommendations for Infinity Pharmaceuticals (NASDAQ:INFI)

Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.